{"disease":{"id":"open","name":"open"},"drugs":{"marketed":[{"drug_id":"rituxan","indication_name":"Thrombotic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituxan","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":45,"revenue":"3800","mechanism":""},{"drug_id":"efgartigimod","indication_name":"Immune thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Efgartigimod","company_name":"M. Peter Marinkovich","drug_phase":"marketed","molecular_target":"FcRn","drug_class":"Endoglycosidase [EPC]","quality_score":58,"revenue":"2500","mechanism":"Efgartigimod alfa binds to FcRn, reducing circulating IgG, while hyaluronidase increases subcutaneous permeability."},{"drug_id":"efgartigimod-alfa","indication_name":"Immune thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyvgart","generic_name":"EFGARTIGIMOD ALFA","company_name":"Argenx Bv","drug_phase":"marketed","molecular_target":"IgG receptor FcRn large subunit p51","drug_class":"Endoglycosidase [EPC]","quality_score":70,"revenue":"2500","mechanism":"Vyvgart works by binding to the p51 subunit of the FcRn receptor, preventing it from recycling antibodies back into the bloodstream."},{"drug_id":"romiplostim","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nplate","generic_name":"ROMIPLOSTIM","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist [EPC]","quality_score":70,"revenue":"1524.0","mechanism":"Nplate works by binding to the thrombopoietin receptor to stimulate platelet production."},{"drug_id":"nivestym","indication_name":"Congenital neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neupogen","generic_name":"Filgrastim-Aafi","company_name":"Amgen","drug_phase":"marketed","molecular_target":"G-CSF receptor (granulocyte colony-stimulating factor receptor)","drug_class":"Colony-stimulating factor (CSF); leukocyte growth factor","quality_score":10,"revenue":"1434.0","mechanism":"Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation."},{"drug_id":"nivestym","indication_name":"Cyclical neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neupogen","generic_name":"Filgrastim-Aafi","company_name":"Amgen","drug_phase":"marketed","molecular_target":"G-CSF receptor (granulocyte colony-stimulating factor receptor)","drug_class":"Colony-stimulating factor (CSF); leukocyte growth factor","quality_score":10,"revenue":"1434.0","mechanism":"Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation."},{"drug_id":"nivestym","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neupogen","generic_name":"Filgrastim-Aafi","company_name":"Amgen","drug_phase":"marketed","molecular_target":"G-CSF receptor (granulocyte colony-stimulating factor receptor)","drug_class":"Colony-stimulating factor (CSF); leukocyte growth factor","quality_score":10,"revenue":"1434.0","mechanism":"Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation."},{"drug_id":"nivestym","indication_name":"Chronic idiopathic neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neupogen","generic_name":"Filgrastim-Aafi","company_name":"Amgen","drug_phase":"marketed","molecular_target":"G-CSF receptor (granulocyte colony-stimulating factor receptor)","drug_class":"Colony-stimulating factor (CSF); leukocyte growth factor","quality_score":10,"revenue":"1434.0","mechanism":"Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation."},{"drug_id":"lipegfilgrastim","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lonquex","generic_name":"LIPEGFILGRASTIM","company_name":"Sicor Biotech UAB","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":28,"revenue":"1200","mechanism":""},{"drug_id":"nyvepria","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neulasta","generic_name":"Pegfilgrastim-Apgf","company_name":"Amgen","drug_phase":"marketed","molecular_target":"G-CSF receptor on hematopoietic cells","drug_class":"Colony-stimulating factor","quality_score":10,"revenue":"1200","mechanism":"Colony-stimulating factor binding hematopoietic cell surface receptors to stimulate proliferation and differentiation."},{"drug_id":"eltrombopag","indication_name":"Thrombocytopenia in Chronic Hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Promacta","generic_name":"ELTROMBOPAG","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist","quality_score":80,"revenue":"569","mechanism":"Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."},{"drug_id":"eltrombopag","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Promacta","generic_name":"ELTROMBOPAG","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist","quality_score":80,"revenue":"569","mechanism":"Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."},{"drug_id":"nab-paclitaxel","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"nab-paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":57,"revenue":"368","mechanism":""},{"drug_id":"paclitaxel","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor [EPC]","quality_score":76,"revenue":"368","mechanism":""},{"drug_id":"nabpaclitaxel","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"Nabpaclitaxel","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":null,"revenue":"368","mechanism":"Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division."},{"drug_id":"rilzabrutinib","indication_name":"persistent or chronic immune thrombocytopenia (ITP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wayrilz","generic_name":"RILZABRUTINIB","company_name":"Genzyme Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":48,"revenue":null,"mechanism":"Wayrilz works by blocking a specific enzyme that helps platelet-destroying immune cells function."},{"drug_id":"indigotindisulfonate","indication_name":"visualization aid in the cystoscopic assessment of the integrity of the ureters in adults following urological and gynecological open, robotic, or endoscopic surgical procedures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bludigo","generic_name":"INDIGOTINDISULFONATE","company_name":"Provepharm Sas","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Bludigo works by emitting a blue fluorescence when exposed to ultraviolet light, allowing for visualization of the ureters."},{"drug_id":"hydrocortisone-succinate","indication_name":"Acquired thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-succinate","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"neupogen","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neupogen","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"neupogen","indication_name":"Chronic idiopathic neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neupogen","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"neupogen","indication_name":"Congenital neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neupogen","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"neupogen","indication_name":"Cyclical neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neupogen","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"azathioprine","indication_name":"Refractory idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imuran","generic_name":"AZATHIOPRINE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Purine Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"argatroban","indication_name":"Thrombosis Prevention in Heparin-Induced Thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Argatroban","generic_name":"ARGATROBAN","company_name":"Hikma Pharm Co Ltd","drug_phase":"marketed","molecular_target":"Prothrombin","drug_class":"Anti-coagulant [EPC]","quality_score":63,"revenue":null,"mechanism":"Argatroban works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"argatroban","indication_name":"Thrombosis in Heparin Induced Thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Argatroban","generic_name":"ARGATROBAN","company_name":"Hikma Pharm Co Ltd","drug_phase":"marketed","molecular_target":"Prothrombin","drug_class":"Anti-coagulant [EPC]","quality_score":63,"revenue":null,"mechanism":"Argatroban works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"brimonidine-tartrate","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alphagan","generic_name":"BRIMONIDINE TARTRATE","company_name":"Senju Pharmaceutical Co., Ltd","drug_phase":"marketed","molecular_target":"Alpha-2C adrenergic receptor","drug_class":"alpha-Adrenergic Agonist","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"clonidine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Catapres-Tts-1","generic_name":"CLONIDINE","company_name":"Lavipharm","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"Central alpha-2 Adrenergic Agonist","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"dorzolamide","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trusopt","generic_name":"DORZOLAMIDE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Carbonic Anhydrase Inhibitor","quality_score":51,"revenue":null,"mechanism":"Trusopt works by inhibiting the enzyme carbonic anhydrase 2, which is involved in the production of aqueous humor in the eye."},{"drug_id":"carbachol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Miostat","generic_name":"CARBACHOL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"carbachol","quality_score":48,"revenue":null,"mechanism":"Miostat works by mimicking the action of the neurotransmitter acetylcholine to increase the outflow of aqueous humor and reduce intraocular pressure."},{"drug_id":"hydrocortisone-acetate","indication_name":"Acquired thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"levobunolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betagan","generic_name":"LEVOBUNOLOL","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"brimonidine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alphagan","generic_name":"BRIMONIDINE","company_name":"Senju Pharmaceutical Co., Ltd","drug_phase":"marketed","molecular_target":"Alpha-2C adrenergic receptor","drug_class":"alpha-Adrenergic Agonist","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"levobetaxolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betaxon","generic_name":"LEVOBETAXOLOL","company_name":"Alcon Pharms Ltd","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"levobetaxolol","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"aceclidine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aceclidin","generic_name":"ACECLIDINE","company_name":"","drug_phase":"marketed","molecular_target":"muscarinic receptors","drug_class":"aceclidine","quality_score":44,"revenue":null,"mechanism":"VIZZ, a pupil-selective miotic, contracts the iris sphincter muscle to improve vision by extending depth of focus."},{"drug_id":"cortisone-acetate","indication_name":"Acquired thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"lusutrombopag","indication_name":"Thrombocytopenic disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mulpleta","generic_name":"LUSUTROMBOPAG","company_name":"Vancocin Italia","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Mulpleta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."},{"drug_id":"sargramostim","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leukine","generic_name":"SARGRAMOSTIM","company_name":"Berlex Labs","drug_phase":"marketed","molecular_target":"Granulocyte macrophage colony-stimulating factor receptor","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":10,"revenue":null,"mechanism":"Leukine works by binding to the granulocyte macrophage colony-stimulating factor receptor, stimulating the production of white blood cells."},{"drug_id":"eflapegrastim-xnst","indication_name":"Febrile neutropenia caused by myelosuppressive anti-cancer drugs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ROLVEDON","generic_name":"EFLAPEGRASTIM-XNST","company_name":"SPECTRUM PHARMS","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Acquired thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Acquired thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"alprostadil","indication_name":"Congenital Heart Defect Requiring Open Patent Ductus Arteriosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caverject","generic_name":"ALPROSTADIL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP3 subtype","drug_class":"Prostaglandin Analog [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"apraclonidine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Iopidine","generic_name":"APRACLONIDINE","company_name":"Harrow Health","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"alpha-Adrenergic Agonist","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"leukine","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Leukine","company_name":"University of Kentucky","drug_phase":"discontinued","molecular_target":"Granulocyte macrophage colony-stimulating factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"clonidin","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Clonidin","company_name":"Medical University of Vienna","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"azopt","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Azopt","company_name":"Alcon Research","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Acquired thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"pegfilgrastim-jmdb","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"FULPHILA","generic_name":"PEGFILGRASTIM-JMDB","company_name":"MYLAN GMBH","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"caplacizumab-yhdp","indication_name":"Thrombotic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CABLIVI","generic_name":"CAPLACIZUMAB-YHDP","company_name":"ABLYNX NV","drug_phase":"marketed","molecular_target":"von Willebrand factor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"methylprednisolone","indication_name":"Acquired thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"methylprednisolone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"hydrocortisone","indication_name":"Acquired thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cepharanthine","indication_name":"Leukopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cepharanthin","generic_name":"CEPHARANTHINE","company_name":"","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase catalytic subunit alpha-1","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"befunolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bentos","generic_name":"BEFUNOLOL","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"befunolol","quality_score":null,"revenue":null,"mechanism":"Bentos works by reducing the production of fluid in the eye, thereby lowering intraocular pressure."},{"drug_id":"physostigmine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cogmine","generic_name":"PHYSOSTIGMINE","company_name":"","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"physostigmine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"eflapegrastim","indication_name":"Febrile neutropenia caused by myelosuppressive anti-cancer drugs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rolvedon","generic_name":"EFLAPEGRASTIM","company_name":"Spectrum Pharms","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":48,"revenue":null,"mechanism":"Rolvedon works by binding to the granulocyte colony-stimulating factor receptor, stimulating the production of white blood cells."},{"drug_id":"metipranolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Optipranolol","generic_name":"METIPRANOLOL","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"brinzolamide","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azopt","generic_name":"BRINZOLAMIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"carbonic anhydrase II","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":48,"revenue":null,"mechanism":"Brinzolamide reduces intraocular pressure by inhibiting carbonic anhydrase II, decreasing aqueous humor secretion."},{"drug_id":"triamcinolone","indication_name":"Acquired thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Acquired thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"xalatan","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xalatan","company_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"epinephrine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epipen","generic_name":"epinephrine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Epipen works by stimulating the alpha-1D adrenergic receptor to rapidly increase heart rate, blood pressure, and bronchodilation."},{"drug_id":"latanoprost","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xalatan","generic_name":"LATANOPROST","company_name":"Thea Pharma","drug_phase":"marketed","molecular_target":"Prostaglandin F2-alpha receptor","drug_class":"Prostaglandin Analog [EPC]","quality_score":75,"revenue":null,"mechanism":"Xalatan works by increasing the outflow of fluid from the eye, reducing pressure."},{"drug_id":"travoprost","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Travatan","generic_name":"TRAVOPROST","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin F2-alpha receptor","drug_class":"Prostaglandin Analog [EPC]","quality_score":10,"revenue":null,"mechanism":"Travatan works by increasing the outflow of fluid from the eye to reduce pressure."},{"drug_id":"dichlorphenamide","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keveyis","generic_name":"DICHLORPHENAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Keveyis works by inhibiting the enzyme carbonic anhydrase, which is involved in the production of aqueous humor in the eye."},{"drug_id":"bimatoprost","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lumigan","generic_name":"BIMATOPROST","company_name":"","drug_phase":"marketed","molecular_target":"Aldo-keto reductase family 1 member C3","drug_class":"Prostaglandin Analog [EPC]","quality_score":75,"revenue":null,"mechanism":"Lumigan works by increasing the outflow of fluid from the eye to reduce pressure."},{"drug_id":"methazolamide","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neptazane","generic_name":"METHAZOLAMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 3","drug_class":"methazolamide","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"avatrombopag","indication_name":"Thrombocytopenic disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doptelet","generic_name":"AVATROMBOPAG","company_name":"Akarx Inc","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Doptelet works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."},{"drug_id":"nipent","indication_name":"Hairy cell leukemia patients with neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nipent","generic_name":"Pentostatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Adenosine deaminase (ADA)","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"nipent","indication_name":"Hairy cell leukemia patients with thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nipent","generic_name":"Pentostatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Adenosine deaminase (ADA)","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"acetazolamide","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"pegfilgrastim","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neulasta","generic_name":"PEGFILGRASTIM","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":70,"revenue":null,"mechanism":"Neulasta stimulates the production of white blood cells by binding to their receptors."},{"drug_id":"lidocaine-hydrochloride-and-epinephrine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride And Epinephrine","generic_name":"Epinephrine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Epinephrine works by stimulating the alpha-1D adrenergic receptor to increase heart rate and blood pressure, and to constrict blood vessels."},{"drug_id":"carteolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ocupress","generic_name":"CARTEOLOL","company_name":"","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"fostamatinib","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavalisse","generic_name":"FOSTAMATINIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Tavalisse works by blocking the activity of the FLT3 enzyme, which is involved in the production of platelets."},{"drug_id":"fostamatinib","indication_name":"Immune thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavalisse","generic_name":"FOSTAMATINIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Tavalisse works by blocking the activity of the FLT3 enzyme, which is involved in the production of platelets."},{"drug_id":"ruxience","indication_name":"Thrombotic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"Rituximab-Pvvr","company_name":"Roche","drug_phase":"marketed","molecular_target":"CD20 antigen on pre-B and mature B-lymphocytes","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC."},{"drug_id":"rituximab","indication_name":"Thrombotic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituximab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."},{"drug_id":"dipivefrine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dipivefrin","generic_name":"dipivefrine","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"Adrenergic Receptor Agonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"caplacizumab","indication_name":"Thrombotic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calibvi","generic_name":"CAPLACIZUMAB","company_name":"Ablynx Nv","drug_phase":"marketed","molecular_target":"von Willebrand factor","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Calibvi works by binding to von Willebrand factor, preventing it from interacting with platelets and forming blood clots."},{"drug_id":"pilocarpine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Salagen","generic_name":"PILOCARPINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Cholinergic Receptor Agonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"lepirudin","indication_name":"Thrombosis in Heparin Induced Thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Refludan","generic_name":"LEPIRUDIN","company_name":"","drug_phase":"marketed","molecular_target":"Prothrombin","drug_class":"Anti-coagulant","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"cefuroxime","indication_name":"Open Heart Surgery Infection Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinacef","generic_name":"CEFUROXIME","company_name":"GSK","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Cephalosporin Antibacterial","quality_score":65,"revenue":null,"mechanism":"Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"latanoprostene-bunod","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyzulta","generic_name":"LATANOPROSTENE BUNOD","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Prostaglandin F2-alpha receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Vyzulta works by activating the Prostaglandin F2-alpha receptor, which increases the outflow of aqueous humor from the eye, thereby reducing intraocular pressure."},{"drug_id":"netarsudil","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rhopressa","generic_name":"NETARSUDIL","company_name":"Alcon Labs Inc","drug_phase":"marketed","molecular_target":"rho kinase","drug_class":"Rho Kinase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Netarsudil reduces intraocular pressure by increasing aqueous humor outflow through the trabecular meshwork."},{"drug_id":"betaxolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betoptic","generic_name":"BETAXOLOL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":10,"revenue":null,"mechanism":"Betaxolol works by blocking the beta-1 adrenergic receptor in the heart and eyes, reducing heart rate and pressure, and decreasing intraocular pressure."},{"drug_id":"echothiophate","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phospholine Iodide","generic_name":"ECHOTHIOPHATE","company_name":"Fera Pharms Llc","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Cholinesterase Inhibitor","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"betamethasone","indication_name":"Acquired thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"betamethasone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"cortisol","indication_name":"Acquired thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Acquired thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"neulasta","indication_name":"Chemotherapy-induced neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neulasta","company_name":"Columbia University","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"epinephrin","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Epinephrin","company_name":"United States Naval Medical Center, San Diego","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"travatan","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Travatan","company_name":"Alcon Research","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Acquired thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"abraxane","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abraxane","company_name":"The First Affiliated Hospital with Nanjing Medical University","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prostavasin","indication_name":"Congenital Heart Defect Requiring Open Patent Ductus Arteriosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prostavasin","company_name":"Hannover Medical School","drug_phase":"phase_2","molecular_target":"Cation channel sperm-associated protein 1, Cation channel sperm-associated protein 2, Cation channel sperm-associated protein 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"salagen","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Salagen","company_name":"Alberta Health services","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Acquired thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"taxol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxol","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Idiopathic thrombocytopenic purpura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"nplate","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nplate","company_name":"Nantes University Hospital","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Secondary thrombocytopenia in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Erythroblastopenia (RBC anemia)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Idiopathic thrombocytopenic purpura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Secondary thrombocytopenia in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Erythroblastopenia (RBC anemia)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"filgrastim-txid","indication_name":"Febrile Neutropenia in Nonmyeloid Malignancies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NYPOZI","generic_name":"FILGRASTIM-TXID","company_name":"TANVEX BIOPHARMA USA INC","drug_phase":"marketed","molecular_target":"Specific cell surface receptors on hematopoietic cells","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":50,"revenue":null,"mechanism":"G-CSF binds to specific receptors on hematopoietic cells, stimulating neutrophil production and function."},{"drug_id":"filgrastim-txid","indication_name":"Neutropenia in BMT","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NYPOZI","generic_name":"FILGRASTIM-TXID","company_name":"TANVEX BIOPHARMA USA INC","drug_phase":"marketed","molecular_target":"Specific cell surface receptors on hematopoietic cells","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":50,"revenue":null,"mechanism":"G-CSF binds to specific receptors on hematopoietic cells, stimulating neutrophil production and function."},{"drug_id":"filgrastim-txid","indication_name":"Severe Chronic Neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NYPOZI","generic_name":"FILGRASTIM-TXID","company_name":"TANVEX BIOPHARMA USA INC","drug_phase":"marketed","molecular_target":"Specific cell surface receptors on hematopoietic cells","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":50,"revenue":null,"mechanism":"G-CSF binds to specific receptors on hematopoietic cells, stimulating neutrophil production and function."},{"drug_id":"chembl-chembl1200962","indication_name":"Empiric Therapy for Febrile Neutropenic Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFEPIME HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"fostamatinib","indication_name":"Thrombocytopenia in Chronic ITP","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavalisse","generic_name":"FOSTAMATINIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Tavalisse works by blocking the activity of the FLT3 enzyme, which is involved in the production of platelets."},{"drug_id":"acetazolamide","indication_name":"Chronic simple (open-angle) glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"voriconazole","indication_name":"Candidemia in non-neutropenic patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VORICONAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"voriconazole","indication_name":"Candidemia in Non-neutropenic Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VORICONAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"dichlorophen","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Didroxan","generic_name":"DICHLOROPHEN","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1","drug_class":"dichlorophen","quality_score":23,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":128,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04655456","title":"Feasibility of Estimating the Prevalence of Malnutrition, Frailty and Sarcopenia in Older People in UK Biobank, Cross-sectional Study: A Study Protocol","phase":"","overall_status":"COMPLETED","enrollment_count":381000,"lead_sponsor_name":"University of Manchester","has_results":false},{"nct_id":"NCT05095844","title":"National Vaccine Adverse Event Reporting Survey and Etiology","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Neuroganics LLC","has_results":false},{"nct_id":"NCT07094295","title":"Perioperative Blood Transfusion and Increased One-year Mortality","phase":"","overall_status":"COMPLETED","enrollment_count":97443,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT04381611","title":"INTEGRAL Study: A Longitudinal Study of Surgeries and Lasers in Glaucoma: Long-term Results and Success Predictors Analysed From a Large-scale Retrospective and Prospective Glaucoma Register","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"Dr. Kaweh Mansouri","has_results":false},{"nct_id":"NCT07308314","title":"Taining Golden Lake Comprehensive Chronic Disease Management Initiative","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT03569735","title":"Nanshan Elderly Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06279078","title":"Long-term Effect of Steroid on Metabolic Diseases in Asthmatics","phase":"","overall_status":"COMPLETED","enrollment_count":19968,"lead_sponsor_name":"Ajou University School of Medicine","has_results":false},{"nct_id":"NCT03916289","title":"A Tiered Management System of Osteoporosis in China","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05345561","title":"Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia","phase":"","overall_status":"COMPLETED","enrollment_count":14390,"lead_sponsor_name":"Rallybio","has_results":false},{"nct_id":"NCT03820960","title":"Risk Factors for Thrombosis in Immune Thrombocytopenia","phase":"","overall_status":"COMPLETED","enrollment_count":10039,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT06380777","title":"Establishment and Application of Digital Diagnosis and Treatment System for Sarcopenia","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT07205510","title":"Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT03523962","title":"Pre-operative Alcohol Skin Solutions in Fractured Extremities","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":8485,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":true},{"nct_id":"NCT06614699","title":"Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Colorectal Cancer Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8000,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT05141565","title":"The Kunshan Elderly Health Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5945,"lead_sponsor_name":"Soochow University","has_results":false},{"nct_id":"NCT07151365","title":"Plant-based Diets and Healthy Aging","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"National Health Research Institutes, Taiwan","has_results":false},{"nct_id":"NCT00523341","title":"Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4550,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06606912","title":"Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Gastric Cancer Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4000,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT02728596","title":"S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)","phase":"NA","overall_status":"COMPLETED","enrollment_count":3665,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT04067375","title":"Towards Routine HPA-screening In Pregnancy to Prevent FNAIT","phase":"","overall_status":"COMPLETED","enrollment_count":3660,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT04079868","title":"Models of Primary Osteoporosis Screening in Male Veterans","phase":"NA","overall_status":"COMPLETED","enrollment_count":3512,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT05937828","title":"OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT05688306","title":"To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":3494,"lead_sponsor_name":"Liaoning Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT04547478","title":"L1 M1 of LDCT for Low Muscle Mass Measurement","phase":"","overall_status":"COMPLETED","enrollment_count":3304,"lead_sponsor_name":"Far Eastern Memorial Hospital","has_results":false},{"nct_id":"NCT06727669","title":"Longitudinal Cohort of Thrombosis and Hemostasis Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT03695224","title":"Matching Glaucoma With Impaired Cognition","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06558617","title":"Evaluating SARC-F, SARC-CalF, and Calf Circumference as Diagnostic Tools for Sarcopenia in Thai Older Adults: Results From a Nationwide Study","phase":"","overall_status":"COMPLETED","enrollment_count":2543,"lead_sponsor_name":"Siriraj Hospital","has_results":false},{"nct_id":"NCT07414004","title":"Comparison of Prognosis Between Open Pancreatic Surgery With Vein Resection and Reconstruction Versus Minimally Invasive Pancreatic Surgery With Vein Resection and Reconstruction for Pancreatic Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2451,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT06676904","title":"Neonatal Platelet Transfusion Threshold Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":2433,"lead_sponsor_name":"NICHD Neonatal Research Network","has_results":false},{"nct_id":"NCT06121791","title":"Abdominal Skeletal Muscle Compartments in Turkish Children","phase":"","overall_status":"COMPLETED","enrollment_count":2168,"lead_sponsor_name":"Istanbul Physical Medicine Rehabilitation Training and Research Hospital","has_results":false},{"nct_id":"NCT03618810","title":"Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT02958462","title":"Pre-myeloid Cancer and Bone Marrow Failure Clinic Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07068425","title":"Longitudinal Observational Study on Immune Thrombocytopenia","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06295965","title":"Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT01853085","title":"A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons","phase":"","overall_status":"COMPLETED","enrollment_count":1830,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT06314516","title":"Influence of Nutrition and Sarcopenia on Esophageal Cancer Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":1717,"lead_sponsor_name":"Benaroya Research Institute","has_results":false},{"nct_id":"NCT03385304","title":"Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1638,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":true},{"nct_id":"NCT03815175","title":"XIENCE 28 USA Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":1605,"lead_sponsor_name":"Abbott Medical Devices","has_results":true},{"nct_id":"NCT06659484","title":"Health Data from Well on My Legs Program","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06434155","title":"Social History and Glaucoma Progression","phase":"","overall_status":"COMPLETED","enrollment_count":1584,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT01999348","title":"A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting","phase":"","overall_status":"COMPLETED","enrollment_count":1553,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT05634005","title":"Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence","phase":"NA","overall_status":"COMPLETED","enrollment_count":1543,"lead_sponsor_name":"University of Utah","has_results":false},{"nct_id":"NCT06011902","title":"A 6-month Follow-up Study of Patients With Severe Fever With Thrombocytopenia Syndrome","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT03846414","title":"Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06593015","title":"Protocol for Muscle Attenuation Cut-offs in Cirrhosis","phase":"","overall_status":"COMPLETED","enrollment_count":1296,"lead_sponsor_name":"University of Roma La Sapienza","has_results":false},{"nct_id":"NCT03835598","title":"Post-Operative Thrombocytopenia After Bio-prosthesis Implantation","phase":"","overall_status":"COMPLETED","enrollment_count":1233,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT07211321","title":"Linking Diet, Inflammation, Gut Microbiota, and Sarcopenia: A Cross-Sectional Study","phase":"","overall_status":"RECRUITING","enrollment_count":1220,"lead_sponsor_name":"Jianhua Ma","has_results":false},{"nct_id":"NCT05339919","title":"Relationship Between Liver Cancer and Sarcopenia","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"First Affiliated Hospital of Wenzhou Medical University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}